IRCT20200105046010N19尚未招募未知
Pharmacokinetic assessments of Fampridine tablet 10mg extended release in comparison with brand drugs FAMPYRA
Pharan shimi Pharmaceutical Company0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 60 years（—）
- 性别
- All
入选标准
- •General health
- •Body Mass Index (BMI) between 18-28
- •Informed consent
- •Age between 18-60
- •Both male and female
排除标准
- •Alcohol & Drug addiction
- •Hypersensitivity to the drug
研究者
相似试验
招募中
3 期
Fampridine effect on Parkinson disease symptomsParkinson's diseaseParkinson disease.IRCT20230905059361N1Shahre-kord University of Medical Sciences62
招募中
不适用
In-vivo Bioequivalence Test of YUNIMIDE® tablet with brand drugs (VIMPAT®200mg UCB Pharma, Belgium)IRCT20200105046010N18Tabriz University of Medical Sciences24
尚未招募
不适用
In vivo study of famotidine tablet 40 mgIRCT20230222057495N1Aria Pharmaceutical Company24
招募中
不适用
In-vivo Bioequivalence Test of Neotadin® tablet with brand drugs (AERIUS® 5mg, FC Schering-Plough Belgium).In this study, the disease is not examined. Subject bioequivalence test and reference tablets Desloratadine studied..IRCT20200105046010N21ABIDI Pharmaceutical Company24
进行中（未招募）
不适用
A Pilot Pharmacodynamic/Pharmacokinetic Study of Fluticasone Propionate Administered as a Dry Powder in Patients with Asthma.AsthmaEUCTR2009-017099-25-GBOriel Therapeutics Inc30